Elanix Biotechnologies raises CHF5 million

Elanix Biotechnologies develops and commercializes tissue regeneration products for acute wound care, dermatological and gynecological applications, and provides services in cell technologies. The company has resolved to implement a capital increase against cash contribution from authorized capital by up to 1,133,200 New Shares, offering an indirect subscription right to shareholders. All 1,133,200 New Shares have been fully placed within the scope of the pre-emptive rights offering and a private placement. The capital increase was oversubscribed due to the high level of interest, hence subscriptions had to be re-allotted equally.

The subscription price per New Share amounted to EUR 4.20. In total the gross placement volume amounts to approx. EUR 4.76 million which will be used to cover the operational expenses of the Company and the further development of marketing the Company's main product GynRepair(R), which is already available in Switzerland, within the European Union as of Q2 2017.

The company was founded in 2013 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. The Company is headquartered in Nyon, Switzerland, with offices in Potsdam, and is listed on the Frankfurt stock exchange.

(SK)